Sarilumab  (Synonyms: Anti-Human IL6Rα, Human Antibody)

Sarilumab is a monoclonal antibody targeting IL6 that binds to IL6R and blocks the binding of IL6, thereby inhibiting the activation of the downstream STAT3 phosphorylation signaling pathway. In tumor cells with active IL6/STAT3 signaling pathways, Sarilumab induces Apoptosis and inhibits cell growth. Sarilumab is applicable to research related to prostate cancer, lung cancer and rheumatoid arthritis^[1][2].

Human IgG1(D356E/L358M) kappa

Human

Sarilumab blocks basal STAT3 phosphorylation in DU145, Calu3 and A549 human tumor cell lines with autocrine IL6/STAT3 signaling pathway in vitro, and exerts inhibitory effects on cell lines exhibiting autocrine IL6/STAT3 signaling^[1].
Sarilumab enhances tumor cell apoptosis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

3570  [NCBI]

P08887

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

144.12 kDa

1189541-98-7

Liquid

Colorless to light yellow

[Sarilumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized IL-6R alpha Protein, Human can bind Sarilumab. The EC₅₀ for this effect is 34.98 ng/mL.

• [1]. Li Zhang, et al. Sarilumab (REGN88), a fully-human anti-IL6R antibody, inhibits tumor growth in preclinical models, as a single agent and in combination with the VEGF blocker
  aflibercept. Cancer Res (2012) 72 (8_Supplement): 2723.

  [2]. McCarty D, et al. Efficacy and safety of sarilumab in patients with active rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2018 Mar;10(3):61-67.  [Content Brief]